top of page
Latest News
03/04/2025
We have received an assignment of a patent for the treatment of refractory cancer (pancreatic cancer, etc.) with three existing pharmaceuticals.
The results of an investigator-initiated clinical trial in which two (Nivolumab + Metformin) of the three drugs described in the patent were administered have showed survival of more than 7 years in a patient among advanced pancreatic cancer (Sato R, Hotta K, Kubo T, et al. (February 14, 2025) Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Cureus 17(2). We are going to license the treatment method using the three-drug administration described in the patent to medical institutions from now on.
02/14/2025
Our headquater has moved with business expansion.
05/01/2023
We've redesigned our website.
01/15/2023
Our headquater has moved with business expansion.
bottom of page